Meds, Mind, Body & Benefits > Research News & Studies

FDA NEWS RELEASE

(1/1)

skycee:
The U.S. Food and Drug Administration today approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.

Diarrhea is experienced by many HIV/AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies. Fulyzaq is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite. Patients take Fulyzaq two times a day to manage watery diarrhea due to the secretion of electrolytes and water in the gastrointestinal tract.


Full story can be found below

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm

Navigation

[0] Message Index

Go to full version